ESTRO 2024 - Abstract Book

S1372

Clinical - Head & neck

ESTRO 2024

adjusted for age, smoking status, Eastern Cooperative Oncology Group performance status (ECOG PS), and Adult Comorbidity Evaluation-27 (ACE-27) comorbidity score.

Results:

Data for 282 patients was available. 143 (50.7%) had p16-positive tumours (all oropharynx), and 139 (49.3%) p16 negative tumours (68 (48.9%) larynx, 27 (19.4%) oral cavity, 23 (16.5%) oropharynx, and 21 (15.1%) hypopharynx). Patients in the p16-negative group were older (median age 66 vs 61 years) with more current smokers (32.8% vs 11.6%) and patients with PS 2-3 (16.5% vs 5.6%) compared to those within the p16-positive group. Figure 1 presents the percentage of p16-positive and p16-negative patients who reported problems with each HR-QoL domain. Patients with p16-negative HNSCC reported more problems with mobility (33.1% vs 16.1%, p=0.002), self-care (23.0% vs 8.4%, p=0.002) and usual activities (42.4% vs 23.1%, p=0.002) than patients with p16-positive HNSCC. There was no significant difference between groups for pain or discomfort (64.7% vs 62.2%, p=0.753) or anxiety or depression (59.0% vs 51.7%, p=0.337). On univariable ordinal regression, patients with p16-negative disease were more likely to have more severe mobility, self-care and usual activities scores compared to p16-positive patients (Table 1). On multivariable ordinal regression, patients with p16-negative disease were more likely to have more severe problems with performing their usual activities than p16-positive patients.

Figure 1 Percentage of p16-positive and p16-negative patients reporting problems (a score greater than 1) within each HR-QoL domain.

Table 1 Results of univariable and multivariable ordinal regression evaluating associations between P16 status (reference is p16-positive) and each EQ-5D-5L domain.

Conclusion: